SCHEMBL2331315

SCHEMBL2331315

O=C(O)N1CCC(Nc2nc(Cl)nc3ccccc23)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.47
MAPT P10636 3/20 0.45
KMT2A Q03164 3/20 0.45
HTT P42858 2/20 0.45
LMNA P02545 1/20 0.45
NTSR1 P30989 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
WHR1 P49842 1/20 0.44
ACP1 P24666 3/20 0.43
TLR7 Q9NYK1 2/20 0.43
MERTK Q12866 1/20 0.42
NSD2 O96028 1/20 0.42
PDE5A O76074 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
BTK Q06187 2/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
APP P05067 1/20 0.41
SPR P35270 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427753 0.93 KMT2A (0.49) CHEK2MAPTKMT2AHTTLMNA
SCHEMBL1428261 0.88 OGG1 (0.50) MAPTKMT2AHTTLMNANTSR1
SCHEMBL2331523 0.85 BTK (0.52) MAPTKMT2AHTTNSD2MEN1
SCHEMBL2331519 0.85 BTK (0.52) MAPTKMT2AHTTNSD2MEN1
SCHEMBL17614452 0.83 TLR7 (0.51) MAPTKMT2AHTTLMNANTSR1
SCHEMBL26614967 0.82 KDM4E (0.44) CHEK2MAPTKMT2ALMNAKDM4E
SCHEMBL26614960 0.82 KDM4E (0.44) CHEK2MAPTKMT2ALMNAKDM4E
SCHEMBL9911789 0.81 NSD2 (0.53) MAPTKMT2AHTTNSD2KDM4E
SCHEMBL17937493 0.81 PRKCI (0.48) SPRCLK4
SCHEMBL2334216 0.80 EHMT2 (0.68) WHR1NSD2EHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324226-B2 Therapeutic oxy-phenyl-aryl compounds and their use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-12-04 US disclosed
EP-2227460-B1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER REC TECH LTD (GB) 2012-06-20 EP disclosed
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2011-08-18 US disclosed
EP-2227460-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2010-09-15 EP disclosed
WO-2009053694-A1 THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201592-A1 Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use CHEK2, CHEK1, PLK1 CHEK2 1/4885MAPT 299/4885KMT2A 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.